Vertex Secures Hat Trick Of Europe CF Approvals With Nod For Symkevi
Executive Summary
Now that the EMA has followed its US counterpart in granting approval for its cystic fibrosis drug Symkevi, Vertex will once again have to navigate Europe's various reimbursement systems, with observers keeping a close eye on how talks with NICE go.
You may also be interested in...
AbbVie Data Show Skyrizi Tops IL-17 Competitors In Skin Clearance
Skyrizi showed better skin-clearance results than Cosentyx or Taltz in a 52-week study of patients who had suboptimal results on the latter two drugs.
Vertex's CF Three-Drug Combo Excels In Phase III, But Filing Depends On Second Regimen's Results
Vertex duplicated promising efficacy observed in Phase II for its cystic fibrosis triple combo that includes VX-659, but wants to see data expected in early 2019 for a triplet containing VX-445 before filing for approvals.
One Rare Disease Drug’s Access Journey Across The Globe
Infographic: Vertex, the first company to produce a drug to treat the underlying cause of cystic fibrosis, has fought for fair (and high) prices for its medicines to reflect their value as treatments for the cause of a genetic disease. The company has sought innovative reimbursement agreements for its CF products in various countries.